Frontier Medicines announces exclusive licensing agreement for FMC-220, a first-in-class covalent p53 Y220C activator, with LG Chem, Ltd. * LG Chem will receive worldwide rights to FMC-220 outside of Greater China; Frontier will retain full ownership within Greater China * Frontier will receive an upfront payment from LG Chem and is eligible to receive potential development, regulatory, commercial, sales milestones and royalties on net product sales * LG Chem to lead regulatory filings, clinical development, manufacturing and commercialization in their Territory; Frontier retains option for co-development to be eligible to receive certain enhanced payments * In preclinical studies, FMC-220 has demonstrated potency, selective engagement, and durable anti-tumor activity at low doses across a broad range of tumor models BOSTON and SOUTH SAN FRANCISCO, Calif. (April 1, 2026) - Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, announced that the Company has granted LG Chem, Ltd. ("LG Chem"), a leading global company headquartered in South Korea that specializes in life sciences as one of its core businesses, an exclusive worldwide license to develop and commercialize FMC-220 outside of Greater China, with Frontier retaining ownership and full control in Greater China. FMC-220 is Frontier's first-in-class covalent p53 Y220C activator being evaluated for the treatment of solid tumor cancers with TP53 loss-of-function mutations. "This partnership with LG Chem marks an exciting and pivotal step for Frontier and for the FMC-220 program, underscoring the promise of our proprietary Frontier(TM) Platform to address historically challenging targets and deliver differentiated, covalent precision therapies," said Chris Varma, Ph.D., co-founder, chairman, and chief executive officer of Frontier Medicines. "Through this collaboration with LG Chem, the FMC-220 program will continue to advance, progressing toward translating the encouraging preclinical data we have demonstrated to date for FMC-220 into meaningful impact for patients. We are thrilled to partner with LG Chem, whose global development and commercialization expertise will be instrumental in bringing this therapy to patients worldwide." FMC-220 covalently binds the mutant cysteine residue introduced by the Y220C substitution in TP53. TP53 Y220C is a common missense mutation found in approximately 1-3% of cancers, particularly prevalent in solid tumors such as lung, breast, ovarian and colorectal cancers. Preclinical data presented at American Association for Cancer Research (AACR) Annual Meeting 2025 showed that FMC-220 delivers unprecedented potency, selective engagement, and durable anti-tumor activity at low doses across a broad range of tumor models, including those harboring co-mutations such as those in KRAS. Dr. Jeewoong Son, President of LG Chem Life Sciences Company, said, "FMC-220 is an innovative approach that targets genetic mutations with limited existing treatment options," adding that the company will "work to validate its potential as a treatment option that could deliver benefits to patients." Under the terms of the agreement, LG Chem will be responsible for regulatory filings, global clinical development, and commercialization in the licensed territories, and Frontier retains an option for enhanced financial participation through partial funding of the confirmatory clinical trial. Frontier will receive an upfront payment and is eligible to receive additional clinical, regulatory, and commercial milestone payments, and mid-single-digit to double-digit royalties on net sales. FMC-220 was discovered using the Frontier(TM) Platform, integrating chemoproteomics and AI for covalent-based drug discovery. FMC-220 is the second potential first-in-class program to advance from the platform, following FMC-376, a dual ON/OFF KRASG12C inhibitor currently in clinical development. About Frontier Medicines Frontier Medicines is a clinical-stage precision medicine company pioneering groundbreaking medicines to transform treatment for genetically defined patient populations, starting with oncology and immunology. Its proprietary chemoproteomics-powered drug discovery engine, the Frontier(TM) Platform, leverages covalent chemistry and machine learning to unlock difficult-to-drug, disease-causing proteins for drug development. Today, Frontiermeds is advancing a diversified pipeline of wholly owned precision medicines against the most critical drivers of cancer and high-value immunology programs. For more information, please visit www.frontiermeds.com. Follow Frontier on LinkedIn. About LG Chem, Ltd. and LG Chem Life Sciences LG Chem is a leading global chemical company with a diversified business portfolio spanning across petrochemicals, advanced materials, and life sciences. LG Chem Life Sciences, the life sciences business division of LG Chem, is dedicated to developing and delivering innovative medicines across a broad range of therapeutic areas. Guided by its mission to transform people's lives through inspiring science and leading innovation, LG Chem Life Sciences is offering differentiated solutions to its customers. For more information, please visit www.lgchem.com. Media Contacts Frontier Medicines: Ashlea Kosikowski (1AB) (704) 488-7369

Frontier Medicines to present findings on PI3Kα-RAS breaker FMC-242 and ai-powered Frontier(TM) Platform at AACR Annual Meeting 2026. March 17, 2026. BOSTON and SOUTH SAN FRANCISCO, Calif. - Frontier Medicines Corporation, a clinical-stage precision medicines company unlocking the proteome to develop small molecule oncology and immunology drugs against previously undruggable disease-causing targets, today announced that it will present preclinical data on its FMC-242 program, as well as advances from its AI-powered Frontier(TM) Platform, at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22, 2026, in San Diego. FMC-242 is Frontier's first-in-class allosteric breaker of the PI3Kα-RAS interaction that is in preclinical development for the treatment of solid tumors driven by RTK activation, RAS mutations and PI3Kα mutations, as both a single agent and in combination with other therapies including KRAS inhibitors. "We look forward to presenting new preclinical data at AACR demonstrating that FMC-242 drives robust anti-tumor activity both as a monotherapy and in combination with targeted agents, while maintaining a favorable tolerability profile," said Kevin Webster, Ph.D., Chief Scientific Officer of Frontier Medicines. "These findings highlight the potential of selectively disrupting the PI3Kα-RAS interaction to address tumors driven by RTK activation and RAS mutations. Together with new data showcasing our AI-powered Frontier(TM) Platform, this work underscores how systematically mapping the proteome for covalent binding sites enables us to expand the range of high-value cancer targets we can drug and advance precision medicines for patients." Summary of the findings to be presented and poster presentation details are as follows: Title: FMC-242, a highly potent and selective covalent inhibitor of the PI3Kα-RAS interaction, demonstrates robust anti-tumor activity as monotherapy and in combination with targeted therapies Poster Number: 5762 Session Title: Multi-Axis Antineoplastic Agents Session Date & Time: April 21, 2026, 2:00 - 5:00 p.m. PT Location: Poster Section 14, San Diego Convention Center Summary of Findings: FMC-242 is a first-in-class, potent, selective, orally bioavailable covalent allosteric breaker of the PI3Kα-RAS interaction. In cell line- and patient-derived xenograft models with HER2 amplification and/or KRAS mutations, FMC-242 demonstrated potent anti-tumor activity with favorable tolerability and no effect on insulin signaling or blood glucose. In combination with EGFR inhibitors, KRASG12C inhibitors (including FMC-376), and pan-RAS/KRAS agents, FMC-242 further enhanced anti-tumor activity, supporting its potential as a differentiated monotherapy and combination approach. Title: Finding Goldilocks: How AI-powered covalent drug discovery removes the "un" from "undruggable" Poster Number: 4183 Session Title: Integrative Computational Approaches 2 Session Date & Time: April 21, 2026, 9:00 a.m. - 12:00 p.m. PT Location: Poster Section 4, San Diego Convention Center Summary of Findings: Application of the Frontier(TM) Platform, which integrates chemoproteomics, covalent chemistry, and machine learning, has enabled identification of selective covalent small-molecule leads across high-value cancer targets, including historically difficult drivers such as KEAP1, ADAR, DHX9, PTPN11, and MYC. The platform maps covalent binding sites across the proteome and applies AI-guided predictive modeling and optimized covalent fragment libraries to accelerate compound design, expanding the range of tractable oncogenic targets previously considered undruggable. About FMC-242 FMC-242 is a first-in-class allosteric breaker of the PI3Kα-RAS interaction that breaks the interaction between PI3Kα and RAS to inhibit downstream signaling in tumors without impacting normal functions such as glucose homeostasis. The mechanism of action inhibits RAS driven PI3Kα-AKT signaling in tumors while minimizing the off-target effects and toxicities commonly associated with the broader class of kinase inhibitors. In preclinical models, FMC-242 has shown potent anti-tumor activity demonstrating the potential to impact patients with lung, colorectal, breast and other cancers that are driven by RTK activation, RAS mutation and PI3Kα mutations either as a single agent or in combination with other therapies including KRAS inhibitors. PI3Kα is the second most commonly mutated oncogene and plays an essential role in both KRAS- and RTK-driven cancers, such as colorectal, lung, and breast cancers, among others. About the Frontier(TM) Platform The Frontier(TM) Platform integrates chemoproteomics, artificial intelligence, and direct-to-biology approaches to accelerate the discovery and development of precision covalent medicines. The platform maps covalent binding sites across the proteome, identifies actionable ligands, and enables rapid optimization of compounds into clinical candidates. Years of systematic data generation have produced CoGT(TM)(the Covalent Ground Truth), which powers Frontier's CovalentAI(TM) engine, a component of the Frontier(TM) Platform and an AI engine that characterizes and scores binding sites for covalent drug discovery, optimizes compounds, and guides the design of Frontier's proprietary covalent fragment library. Profiling this library against the human proteome has yielded Frontier's Druggability Atlas(TM), covering more than 90% of the human proteome. About Frontier Medicines Frontier Medicines is a clinical-stage precision medicine company pioneering groundbreaking medicines to transform treatment for genetically defined patient populations, starting with oncology and immunology. Its proprietary chemoproteomics-powered drug discovery engine, the Frontier(TM) Platform, leverages covalent chemistry and machine learning to unlock difficult-to-drug, disease-causing proteins for drug development. Today, Frontiermeds is advancing a diversified pipeline of wholly owned precision medicines against the most critical drivers of cancer and high-value immunology programs. For more information, please visit www.frontiermeds.com. Follow Frontier on LinkedIn. Media Contact Frontier Medicines: Ashlea Kosikowski (1AB) (704) 488-7369